SCHEMBL2512904

SCHEMBL2512904

COc1ccc(Cn2cc(-c3csc(Nc4nccc(C)n4)n3)c(-c3ccccc3)n2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 8/20 0.44
MEN1 O00255 6/20 0.44
KMT2A Q03164 6/20 0.44
SMN1; SMN2 Q16637 5/20 0.44
MAPT P10636 5/20 0.44
NFKB1 P19838 4/20 0.44
NFKB2 Q00653 4/20 0.44
RELA Q04206 4/20 0.44
GAA P10253 4/20 0.44
ALOX5 P09917 2/20 0.44
RECQL P46063 1/20 0.44
NPC1 O15118 7/20 0.42
ALDH1A1 P00352 1/20 0.42
MCL1 Q07820 1/20 0.42
MAPK1 P28482 1/20 0.41
HTT P42858 1/20 0.41
AMY1A P0DUB6 1/20 0.41
APP P05067 1/20 0.41
SENP8 Q96LD8 1/20 0.41
SENP7 Q9BQF6 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL366183 0.86 MEN1 (0.40) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL369359 0.84 KMT2A (0.35) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL369474 0.84 WNT3A (0.39) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL2536307 0.83 MAPT (0.42) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL369911 0.83 WNT3A (0.37) MEN1KMT2ASMN1; SMN2MAPTGAA
SCHEMBL370330 0.81 WNT3A (0.37) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL370432 0.81 RAB9A (0.45) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL15166604 0.80 ACVR1 (0.33) RAB9AMEN1KMT2ANPC1CYP1A1
SCHEMBL370879 0.79 MEN1 (0.44) RAB9AMEN1KMT2ASMN1; SMN2MAPT
SCHEMBL369452 0.79 KDM1A (0.38) MEN1KMT2ASMN1; SMN2MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9073907-B2 Thiazoles derivatives and their use as positive allosteric modulators of metabotropic glutamate receptors ADDEX PHARMA S.A. (CH) 2015-07-07 US disclosed
EP-2376486-B1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMACEUTICALS SA (CH) 2013-11-06 EP disclosed
US-20110257179-A1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA SA (CH) 2011-10-20 US disclosed
EP-2376486-A1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX Pharma S.A. (CH) 2011-10-19 EP disclosed
WO-2010079239-A1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS ADDEX PHARMA S.A. (CH) 2010-07-15 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110257179-A1 NOVEL THIAZOLES DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS GRM4, GRM2, GRM1 RAB9A 2177/4885MEN1 3967/4885KMT2A 2333/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.